Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes

AIMS: To assess the pharmacokinetics/pharmacodynamics (PK/PD) of dapagliflozin, a sodium‐glucose co‐transporter 2 inhibitor that increases urinary glucose excretion (UGE) and its major metabolite, dapagliflozin‐3‐O‐glucuronide (D3OG), in Japanese patients with type 1 diabetes (T1D) and inadequate gl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Watada, Hirotaka, Shiramoto, Masanari, Ueda, Shinya, Tang, Weifeng, Asano, Michiko, Thorén, Fredrik, Kim, Hyosung, Yajima, Toshitaka, Boulton, David W., Araki, Eiichi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2018
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590304/
https://ncbi.nlm.nih.gov/pubmed/30499157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13593
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi